Related Experiment Video
Updated: May 21, 2026
A Cancer Cell Spheroid Assay to Assess Invasion in a 3D Setting
Published on: November 20, 2015
The Cancer BioChip System: a functional genomic assay for anchorage-independent three-dimensional breast cancer cell
Rula A Abbud-Antaki1, Joie N Marhefka, Aimee L DeLuca
1Falcon Genomics, Inc., 160 North Craig Street, Suite 222, Pittsburgh, PA 15213, USA. rabbud@falcongenomics.com
Abstract:
Advances in genomic research have revealed that each patient has their own unique tumor profile. While silencing RNA (siRNA) screening tests can identify which genes drive tumor cell growth, results obtained from these assays have been limited in their clinical translatability because they employ cell lines growing on flat surfaces. The Cancer BioChip System (CBCS) is a functional screening assay for identification of siRNA capable of inhibiting anchorage-independent three-dimensional (3D) cancer cell growth. Anchorage-independent growth assays are important in vitro predicators of regulators of cancer cell growth. Unique features of the CBCS include a Cancer BioChip, wherein cells incorporate different siRNAs in parallel and grow in a 3D matrix to form colonies that can be quantified using real-time imaging and an image analysis software. Thus, the CBCS can be developed as a tool for personalized identification of targeted cancer therapies.
Insights
This study introduces the Cancer BioChip System (CBCS) for personalized cancer therapy. The CBCS identifies effective silencing RNA (siRNA) to inhibit three-dimensional tumor cell growth, improving clinical translatability for targeted treatments.
Area of Science:
- Oncology
- Genomics
- Biotechnology
Background:
- Genomic research highlights individual tumor profiles.
- Current silencing RNA (siRNA) screening has limited clinical translatability due to 2D cell culture limitations.
- Anchorage-independent growth is a key predictor of cancer cell growth regulation.
Purpose of the Study:
- To introduce a novel functional screening assay, the Cancer BioChip System (CBCS).
- To identify siRNA capable of inhibiting anchorage-independent three-dimensional (3D) cancer cell growth.
- To develop a tool for personalized identification of targeted cancer therapies.
Main Methods:
- Utilizing a Cancer BioChip for parallel siRNA incorporation in cells.
- Culturing cells within a 3D matrix to mimic tumor microenvironments.
- Quantifying colony formation using real-time imaging and image analysis software.
Main Results:
- The CBCS enables functional screening of siRNA in 3D cancer cell cultures.
- The system effectively quantifies siRNA efficacy in inhibiting anchorage-independent growth.
- Demonstrates potential for identifying patient-specific anti-cancer therapeutics.
Conclusions:
- The Cancer BioChip System (CBCS) offers improved clinical translatability for siRNA screening.
- CBCS facilitates the identification of targeted therapies based on individual tumor profiles.
- The system represents a promising tool for personalized oncology.
More Related Videos
07:03Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model
Published on: February 3, 2021
09:53Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography
Published on: August 16, 2020